AXQ Capital LP Sells 39,088 Shares of Sarepta Therapeutics, Inc. $SRPT

AXQ Capital LP reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 72.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 14,619 shares of the biotechnology company’s stock after selling 39,088 shares during the quarter. AXQ Capital LP’s holdings in Sarepta Therapeutics were worth $282,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Byrne Asset Management LLC acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at approximately $33,000. Atlantic Union Bankshares Corp bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $48,000. AlphaQuest LLC raised its holdings in shares of Sarepta Therapeutics by 118.3% in the third quarter. AlphaQuest LLC now owns 2,561 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,388 shares during the last quarter. Covestor Ltd lifted its position in shares of Sarepta Therapeutics by 1,081.8% in the third quarter. Covestor Ltd now owns 2,789 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 2,553 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Sarepta Therapeutics by 285.6% in the third quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 2,288 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SRPT has been the subject of a number of analyst reports. Guggenheim decreased their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Wells Fargo & Company reduced their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, January 27th. Piper Sandler lifted their target price on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada increased their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $33.84.

Sarepta Therapeutics Stock Performance

SRPT opened at $17.45 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $109.50. The business has a 50 day moving average of $20.51 and a 200-day moving average of $20.22. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -2.07, a PEG ratio of 0.48 and a beta of 0.39.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 49.42%. The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same quarter last year, the company posted $1.90 EPS. The firm’s revenue was down 32.7% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insider Activity at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.60% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue topped Street estimates, showing better-than-expected top-line performance for the quarter despite product-specific weakness. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Management emphasized a solid balance sheet and cash position on the call/press release, which can support R&D and the transition period. Press Release: Q4 and Full-Year 2025 Financial Results
• Positive Sentiment: New longer-term and safety data will be presented at the MDA Clinical & Scientific Congress, offering potential catalysts if data are favorable. MDA Conference Presentation Announcement
• Neutral Sentiment: Full earnings materials and the call transcript/slides are available for investors to review management’s details on costs, cash burn and product strategies. Earnings Slides / Press Release
• Negative Sentiment: Earnings per share missed badly: SRPT reported a loss of $3.58/share vs. consensus around a $0.87 loss, a large downside surprise that pressured the stock. MarketBeat Q4 Summary
• Negative Sentiment: Elevidys sales “tumbled,” driving much of the revenue decline vs. prior year and signaling market-share and demand challenges for Sarepta’s key product. Zacks: Sales Beat but Elevidys Sales Tumble
• Negative Sentiment: Revenue declined ~33% year-over-year, underscoring that the company is in a down cycle and must show steady recovery to restore investor confidence. Yahoo Finance: Compared to Estimates
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon replacement), creating near-term leadership uncertainty during a critical turnaround period. Reuters: CEO to Retire
• Negative Sentiment: Company issued cautious 2026 guidance, signaling recovery will be gradual — investors typically punish biotech names that lower near-term visibility into growth. Yahoo Finance: Guidance and Recovery Path

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.